InvestorsHub Logo
Followers 57
Posts 5697
Boards Moderated 0
Alias Born 12/13/2004

Re: dia76ca post# 2116

Wednesday, 05/17/2017 6:23:43 PM

Wednesday, May 17, 2017 6:23:43 PM

Post# of 6034
When combined with BCG, HS-410 turned about 75% of cold tumours into hot tumours. That is great! So far, from a small sample, HS-110 plus Opdivo turned about 60% of cold tumours into hot tumours. The bladder cancer larger sample MAY suggest that this 60% could move even higher in a larger sample.

We are looking at different combinations and different cancer indications, however if HS-110 can turn 60-75% of cold tumours into hot tumours...this is very great news!

The HS-110 plus Opdivo trial is an open trial and both the management and potential partners should be watching the HS-110 data develop...and act accordingly!

And do not forget that the ComPACT(gp96 + Ox40)preclinical data shows even better results than ImPACT(gp96 alone)! And then there is PTX-25. I like our chances!

"The refusal of the real is the number one dogma of our time" Rene Girard

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NHWK News